AZNeuro IMED

Our Science

AZNeuro IMED Areas of Research

AstraZeneca Neuroscience

Neurodegenerative Diseases

We are pursuing pathways and targets that may be beneficial for multiple neurodegenerative diseases. These include mitochondrial dysfunction, protein transmission, autophagy, and neuroinflammation. We have broad disease interests including:

  • Alzheimer’s disease
  • Parkinson’s disease
  • Frontotemporal dementia
  • Huntington’s disease
  • Amyotrophic Lateral Sclerosis (ALS)

Our Science - Neurogenerative Diseases

Psychiatry

The Neuroscience IMED is leveraging recent advances in human genetics to identify targets and pathways for therapeutic intervention as well as capitalising on emerging biology around neuronal circuits known to be dysfunctional in disease. We are focused on novel approaches to meet residual high unmet need in defined patient populations not treated effectively by existing therapies. Some of these areas include:

  • Autism spectrum disorders
  • Refractory major depressive disorder
  • Addiction disorders
  • Behavioral symptoms in dementia

Our Science - Psychiatry

Analgesia

In this area we are focused on targeting pathways that have the potential to provide step-change efficacy compared to existing treatments, agents that provide robust efficacy in add-on settings and that effectively treat non-responders to existing treatments. Our near-term approaches are aimed at:

  • Reducing afferent activation and transmission of nociceptive signals
  • Reducing peripheral sensitization
  • Preventing or reversing central sensitization
  • Modulation of signaling in spinal cord
  • Targeting descending control and affective components of pain

Top